Encyclopedia of Diagnostic Imaging

2008 Edition
| Editors: Albert L. Baert

Contrast Media MR, Organ Specific

  • Peter Reimer
Reference work entry
DOI: https://doi.org/10.1007/978-3-540-35280-8_607
How to cite

Synonyms

Currently, three organ‐specific contrast agents with uptake into hepatocytes followed by variable biliary excretion represent the only clinically approved organ‐specific contrast agents besides iron oxides:

  • Mangafodipir trisodium (Teslascan, GE‐Amersham Health, Oslo, Norway)

  • Gadobenate dimeglumine (MultiHance, Bracco Imaging S.p.A., Milan, Italy)

  • Gadoxetic acid (Primovist, Schering AG, Berlin, Germany).

Enhancement during the distribution phase of contrast agents mainly depends on tumor vascularity (hypovascular vs. hypervascular) and its blood supply while enhancement on delayed images is characterized by the cell specificity of magnetic resonance (MR) contrast agents (extracellular vs. intracellular). Therefore, enhancement characteristics of hepatobiliary contrast agents are applicable to the diagnosis of primary benign and malignant hepatocellular liver tumors (1).

Definition

Mangafodipir Trisodium “Teslascan”

Mangafodipir trisodium is a manganese (Mn) chelate...

This is a preview of subscription content, log in to check access.

Bibliography

  1. 1.
    Earls JP and Bluemke DA (1999) New MR imaging contrast agents. Magn Reson Imaging Clin N An 7(2):255–273Google Scholar
  2. 2.
    Giovagnoni A and Paci E (1996) Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am 4(1):61–72PubMedGoogle Scholar
  3. 3.
    Huppertz A et al (2004) Improved detection of focal liver lesion at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230(1):266–275PubMedCrossRefGoogle Scholar
  4. 4.
    Reimer P, Schneider G, and Schima W (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14(4):559–578PubMedCrossRefGoogle Scholar
  5. 5.
    Rofsky NM and Earls JP (1996) Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging. Magn Reson Imaging Clin N Am 4(1):73–85Google Scholar
  6. 6.
    Schima W et al (1997) Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir. J Magn Reson Imaging 7(1):130–135Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg New York 2008

Authors and Affiliations

  • Peter Reimer
    • 1
  1. 1.Deaprtment of Radiology, Klinikum KarlsruheAcademic Teaching Hospital of the University of Freiburgh Karlsruhe